tradingkey.logo
搜尋

Parabilis Medicines Ord Shs

PBLS
添加自選
28.430USD
+0.740+2.67%
收盤 11-13 16:00(美東)
3.47B總市值
0.00本益比TTM

Parabilis Medicines Ord Shs

28.430
+0.740+2.67%

關於 Parabilis Medicines Ord Shs 公司

Parabilis Medicines, Inc., formerly FOG Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. It is built to develop transformative medicines addressing undruggable protein targets driving human disease. It leverages a proprietary platform to a novel therapeutic modality, Helicons, which are stabilized helical peptides engineered to bind and precisely modulate proteins that reach conventional medicine. Its lead product candidate, zolucatetide, is the first and only investigational therapy that inhibits the b-catenin: TCF interaction, the critical downstream node of the Wnt/b-catenin pathway. Its preclinical pipeline provides Helicon approach and includes programs targeting two key drivers of prostate cancer, the ETS-related gene and the androgen receptor (AR) in its active state (ARON). Helicon discovery platform integrates advanced AI and physics-based computational modeling with peptide synthesis and experimental screening to discover and develop drug candidates.

Parabilis Medicines Ord Shs 簡介

公司代碼- -
公司名稱- -
上市日期- -
CEO- -
員工數量- -
證券類型- -
年結日- -
公司地址- -
城市- -
上市交易所- -
國家- -
郵編- -
電話- -
網址- -
公司代碼- -
上市日期- -
CEO- -

Parabilis Medicines Ord Shs公司高管

名稱
名稱/職務
職務
持股
持股變動
Dr. Craig L. Tendler, M.D.
Dr. Craig L. Tendler, M.D.
Independent Director
Independent Director
--
--
Mr. Rohin Mhatre, Ph.D.
Mr. Rohin Mhatre, Ph.D.
Chief Technical Operations Officer
Chief Technical Operations Officer
--
--
Mr. Thomas (Tom) Kotarakos
Mr. Thomas (Tom) Kotarakos
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Helen Ho, Ph.D.
Dr. Helen Ho, Ph.D.
Chief Business and Strategy Officer
Chief Business and Strategy Officer
--
--
Dr. Fawzi Benzaghou, M.D.
Dr. Fawzi Benzaghou, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Barbara L. Weber, M.D.
Dr. Barbara L. Weber, M.D.
Independent Director
Independent Director
--
--
Mr. Alan M. Sebulsky
Mr. Alan M. Sebulsky
Independent Director
Independent Director
--
--
Dr. Jake Simson, Ph.D.
Dr. Jake Simson, Ph.D.
Independent Director
Independent Director
--
--
Ms. Teresa Jurgensen, J.D.
Ms. Teresa Jurgensen, J.D.
General Counsel
General Counsel
--
--
Dr. Krishna Yeshwant, M.D.
Dr. Krishna Yeshwant, M.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Craig L. Tendler, M.D.
Dr. Craig L. Tendler, M.D.
Independent Director
Independent Director
--
--
Mr. Rohin Mhatre, Ph.D.
Mr. Rohin Mhatre, Ph.D.
Chief Technical Operations Officer
Chief Technical Operations Officer
--
--
Mr. Thomas (Tom) Kotarakos
Mr. Thomas (Tom) Kotarakos
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Helen Ho, Ph.D.
Dr. Helen Ho, Ph.D.
Chief Business and Strategy Officer
Chief Business and Strategy Officer
--
--
Dr. Fawzi Benzaghou, M.D.
Dr. Fawzi Benzaghou, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Barbara L. Weber, M.D.
Dr. Barbara L. Weber, M.D.
Independent Director
Independent Director
--
--

常見問題

Parabilis Medicines Ord Shs的前五大股東是誰?

Parabilis Medicines Ord Shs的前五大股東如下:Dr. Fawzi Benzaghou, M.D.
tradingkey.logo
風險提示:我們的網站和行動應用程式僅提供關於某些投資產品的一般資訊。Finsights 不提供財務建議或對任何投資產品的推薦,且提供此類資訊不應被解釋為 Finsights 提供財務建議或推薦。
投資產品存在重大投資風險,包括可能損失投資的本金,且可能並不適合所有人。投資產品的過去表現並不代表其未來表現。
Finsights 可能允許第三方廣告商或關聯公司在我們的網站或行動應用程式的任何部分放置或投放廣告,並可能根據您與廣告的互動情況獲得報酬。
© 版權所有: FINSIGHTS MEDIA PTE. LTD. 版權所有